RESEARCH

Every year Omikron Italia invests about 12% of its turnover in Research and Development on projects carried  out in collaboration with the most prestigious Italian and foreign Institutes.

The Main Fields of Research are the following:

1. Vasal Contractility and Permeability, for which there is a multi-year framework agreement with a US University Institute;

2. Preclinical development of a new flavonoid;

3. Hemorrhoidal disease:

  • a multicenter, prospective, randomized, controlled, triple-blind Clinical study, performed in an independent manner by the Italian Society of Colo-Rectal Surgery (SICCR) to evaluate the effectiveness of our mixture of flavonoids in the treatment of acute hemorrhoidal disease, has been ended and published in an International Journal;
  • the preclinical development of a new formulation for topical use in the treatment of hemorrhoids is now being performed;

4. Retina:

  • an Experimental Trial on the treatment of Diabetic Retinopathy performed by an Italian University Institute has been ended and published in an International Journal;
  • an Experimental Trial performed by the National Health Institute (Istituto Superiore di Sanità ) in vitro on retina cell cultures and in vivo with rats in order to assess the neuro-protective effect on structural and functional possible alteration on the retinal neuroglia component in the diabetic disease has been ended and published in an International Journal;
  • a Clinical Trial on the Treatment of Diabetic Retinopathy is now being performed;
  • a Clinical Trial on corneal morphology and functionality is now being performed;

5. Glaucoma:

  • the first multicenter Experimentation with citicoline in oral solution, never carried out before on the progression of the campimetric damage in glaucoma patients has been performed and published in an International Journal;
  • the preclinical and clinical development of OMK1®, citicoline and hyaluronic acid in ophthalmic solution (Medical Device CE) and of OMK2®, citicoline, hyaluronic acid and vitamine B12 in ophthalmic solution (Medical Device CE) has been carried out in Italy;
  • a Clinical Trial performed by an Italian Research Institute with citicoline in ophthalmic solution in the treatment of glaucomatous patients has been ended and published in an International Journal;
  • a Clinical Trial is now being performed by an Italian Institute on the treatment of patients with neurodegenerative diseases involving the optic nerve;
  • multicenter Experimentation with citicoline in ophthalmic solution in glaucomatous patients with progression damage is now being performed;
  • the preclinical development of a new formulation for ophthalmic use in the treatment of glaucoma is now being performed;

6. Omikron Italia supported Scientific Research also financing in 2011 a scholarship at the National Health Institute (Istituto Superiore di Sanità), Project for Global Health,  dedicated to young Researchers in the therapy of emerging chronic diseases (diabetes) or neglected diseases (chronic venous ulcers). 

 

Go to top